Browse Studies — Arctuva

Phase 3

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-…

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaCentral Nervous System Leukemia+2 more

Estimated

~$10 – $7,500

Children's Oncology GroupNCT03959085

Observational

Red Blood Cell Transfusion Threshold-Specific Bleeding, Quality of Life and Functional Outcomes in Acute Leukemia Patients With Thrombocytopenia: a Randomized Feasibility Study

This clinical trial evaluates the effects of hemoglobin threshold-specific packed red blood cell (PRBC) transfusions on quality of life and functional outcomes…

Acute Myeloid LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+1 more

Estimated

~$10 – $6,250

University of WashingtonNCT06710418

Phase 1

A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

This phase I trial tests the safety and side effects of B-cell activating factor receptor (BAFFR) chimeric antigen receptor (CAR) T cells and how well they wor…

Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07758673

Phase 2

Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B ac…

B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT02877303